Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 8/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR1B | P28222 | 2/20 | 0.37 |
| ▸ | HTR1D | P28221 | 1/20 | 0.37 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052125 | 0.83 | LTA4H (0.53) | CYP3A4LTA4H | |
| SCHEMBL15959430 | 0.82 | MAPK1 (0.40) | PPARACYP3A4L3MBTL1 | |
| SCHEMBL16472055 | 0.82 | PPARA (0.54) | PPARASMN1; SMN2L3MBTL1 | |
| SCHEMBL15617688 | 0.82 | DRD2 (0.55) | PPARASMN1; SMN2L3MBTL1 | |
| SCHEMBL23574899 | 0.80 | LTA4H (0.58) | PPARACYP3A4SMN1; SMN2LTA4H | |
| SCHEMBL13141262 | 0.80 | HRH3 (0.54) | CYP3A4SMN1; SMN2 | |
| SCHEMBL22623976 | 0.80 | DRD2 (0.50) | PPARASMN1; SMN2L3MBTL1 | |
| SCHEMBL13526893 | 0.80 | APP (0.47) | PPARACYP3A4SMN1; SMN2 | |
| SCHEMBL13526994 | 0.80 | TDP1 (0.53) | PPARASMN1; SMN2L3MBTL1LTA4HHTR1A | |
| SCHEMBL10202896 | 0.79 | KCNA3 (0.62) | PPARALTA4HHTR1BHTR1DKCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993557-B2 | Pyridinedione carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140235608-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235608-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | PPARA 109/4885CYP3A4 552/4885SMN1; SMN2 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.